Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 31 to 45 of 152 results for multiple sclerosis

  1. Glatiramer acetate depot for multiple sclerosis [TSID10620]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  2. Tolebrutinib for treating primary progressive multiple sclerosis [ID6574]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  3. Tolebrutinib for treating primary progressive multiple sclerosis [TSID12166]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  4. Can vitamin D slow down the progression of disability in Multiple Sclerosis (MS)?

    Question Can vitamin D slow down the progression of disability in Multiple Sclerosis (MS)? Any explanatory notes(if...

    Research recommendation
    Published
    9 June 2015

  5. What is the clinical and cost effectiveness of cognitive rehabilitation for people with Multiple sclerosis (MS)?

    people with Multiple sclerosis (MS)? Any explanatory notes(if applicable) Cognitive impairment affects 43–70% of people...

    Research recommendation
    Published
    9 June 2015

  6. What non-pharmacological interventions are effective in reducing spasticity in people with Multiple Sclerosis (MS)?

    with Multiple Sclerosis (MS)? Any explanatory notes(if applicable) Spasticity is a common symptom affecting up to 80% of...

    Research recommendation
    Published
    9 June 2015

  7. News Articles

    treatment option for highly active multiple sclerosis Thousands of people living with a form of multiple sclerosis...

  8. What is the optimal frequency, intensity and form of rehabilitation for mobility problems in people with Multiple Sclerosis (MS)?

    people with Multiple Sclerosis (MS)? Any explanatory notes(if applicable) Reduced mobility is one of the most common...

    Research recommendation
    Published
    9 June 2015

  9. Autologous unmanipulated peripheral blood stem cell therapy for multiple sclerosis

    Topic prioritisation

    Interventional procedures guidance
    Topic prioritisation

  10. Is intravenous methylprednisolone more clinically and cost effective than oral methylprednisolone in people with relapsing–remitting Multiple Sclerosis (MS) and people with secondary progressive MS with continued relapses?

    methylprednisolone in people with relapsing–remitting Multiple Sclerosis (MS) and people with secondary progressive...

    Research recommendation
    Published
    9 June 2015

  11. Subcutaneous ocrelizumab for treating primary progressive or relapsing multiple sclerosis [TSID11895]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  12. News, blogs and podcasts

    treatment option for highly active multiple sclerosis Thousands of people living with a form of multiple sclerosis...

  13. NICE recommends the development of patient registries for multiple sclerosis to capture long-term treatment-related outcomes.

    Question NICE recommends the development of patient registries for multiple sclerosis to capture long-term treatment-related outcomes....

    Research recommendation
    Published
    9 June 2015

  14. Ocrelizumab for treating relapsing–remitting multiple sclerosis in people 10 to 17 years [TSID12164]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  15. NICE recommends further research to better inform future cost-effectiveness models of relapsing-remitting multiple sclerosis. In particular, this research should include a more comprehensive synthesis of available evidence on the underlying disease progression of multiple sclerosis in the UK context, the impact of disability and relapses on preference-based measures of quality of life, and associated resource use and costs.

    better inform future cost-effectiveness models of relapsing-remitting multiple sclerosis. In particular, this research should include a...

    Research recommendation
    Published
    9 June 2015